Volume :
2
Issue :
4
Abstract :
Dry powder inhalers (DPI) are used to cure various lung diseases such as asthma and chronic obstructive pulmonary disease (COPD). DPI typically consist of either drug alone or drug blended with inert carriers like lactose, lucine or mannitol that are FDA-approved for inhalation as lactose and mannitol in an ordered mixture. The use of carrier particles enhances drug particles flowability and increases the inhalation efficiency. Carrier particles can be chosen according to their median particle size, taking into account the fact that an increase in median particle size increases the adhesion force between drug and carrier particles. Carrier particles also decrease the residual fine drug particles that adhere to inhalation devices and capsules upon inhalation of fine drug particles. Inflammation in asthma is present throughout the lungs, but asthma is associated particularly with lymphocytes and eosinophil cells. The highest numbers of eosinophils were found in the walls of non- respiratory bronchioles. And COPD is characterized by airflow obstruction that is not fully reversible and is usually progressive in the long term. It can result in significant disability and impaired quality of life. Smoking is the main cause of COPD. COPD is of two types, i.e., Chronic bronchitis, which involves a long-term cough with mucus and Emphysema, which involves destruction of the lungs over time.